Herbal and Dietary Supplement Hepatotoxicity

ABSTRACT

Herbal and dietary supplements (HDS) are commonly used in the United States and throughout the world. The Dietary Supplement Health and Education Act and public standards set through the U.S. Pharmacopeia provide regulatory framework for these products. These regulations help to ensure the safety of grandfathered and new HDS coming onto the market, and the opportunity to identify and take action against unsafe products that have been distributed. The clinical patterns of presentation and severity of HDS-associated hepatotoxicity can be highly variable, even for the same product. In addition, accurate causality assessment in cases of suspected HDS hepatotoxicity is confounded by infrequent ascertainment of product intake by healthcare providers, under-reporting of HDS use by patients, the ubiquity of HDS and the complexity of their components, and the possibility for product adulteration. Additional measures to prevent HDS-induced hepatotoxicity include greater consumer and provider awareness, increased spontaneous reporting, and reassessment of regulations regarding the manufacturing, distribution, and marketing of these products.

KEYWORDS

Hepatotoxicity - herbal dietary supplements - Dietary Supplement Health and Education Act (DSHEA) - U.S. Pharmacopeia (USP)

REFERENCES

• 1 Kennedy J. Herb and supplement use in the US adult population.  Clin Ther. 2005;  27(11) 1847-1858
• 2 FDA Web site .Federal Food, Drug, and Cosmetic Act (FD&C Act). Available at: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/default.htm Accessed May 31, 2009
• 3 Barnes P M, Powell-Griner E, McFann K, Nahin R L. Complementary and Alternative Medicine Use Among Adults: United States, 2002. Hyattsville, MD; National Center for Health Statistics 2004 Advance Data From Vital and Health Statistics, No. 343
• 4 Ni H, Simile C, Hardy A M. Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey.  Med Care. 2002;  40(4) 353-358
• 5 Eisenberg D M, Davis R B, Ettner S L et al.. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey.  JAMA. 1998;  280(18) 1569-1575
• 6 Brevoort P. The booming US botanical market: a new overview.  HerbalGram. 1998;  44 33-46
• 7 Ernst E, Pittler M H. Herbal medicine.  Med Clin North Am. 2002;  86(1) 149-161
• 8 Thyagarajan S P, Jayaram S, Gopalakrishnan V, Hari R, Jeyakumar P, Sripathi M S. Herbal medicines for liver diseases in India.  J Gastroenterol Hepatol. 2002;  17(Suppl 3) S370-S376
• 9 National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases .Obesity Education Initiative. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. NIH Publication No. 98–4083; Bethesda, MD 1998 Available at: http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf Accessed May 31, 2009
• 10 Blanck H M, Serdula M K, Gillespie C et al.. Use of nonprescription dietary supplements for weight loss is common among Americans.  J Am Diet Assoc. 2007;  107(3) 441-447
• 11 U.S. Food and Drug Administration .Consumer information on dietary supplements. Available at: http://www.fda.gov/Food/DietarySupplements/ConsumerInformation Accessed May 31, 2009
• 12 U.S. Food and Drug Administration .Transcripts of FDA press conference on dietary supplements. Available at: http://www.fda.gov/downloads/NewsEvents/Newsroom/MediaTranscripts/ucm123597.pdf Accessed May 31, 2009
• 13 U.S. Food and Drug Administration .Guidance, Compliance & Regulatory Information. Available at: http://www.fda.gov/food/DietarySupplements/GuidanceComplianceRegulatoryInformation Accessed May 31, 2009
• 14 The United States Pharmacopeia (USP) .About USP—an overview. Available at: http://www.usp.org/aboutUSP Accessed on May 31, 2009
• 15 Bhattacharyya L, Cecil T, Dabbah R USP Council of Experts Executive Committee et al. The value of USP public standards for therapeutic products.  Pharm Res. 2004;  21(10) 1725-1731
• 16 De Smet P A. Herbal medicine in Europe—relaxing regulatory standards.  N Engl J Med. 2005;  352(12) 1176-1178
• 17 Official Journal of the European Union. Directive 2004/24/EC of the European Parliament and of the council amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the community code relating to medicinal products for human use. Available at: http://www.mhra.gov.uk/home/groups/es-herbal/documents/websiteresources/con009359.pdf Accessed May 31, 2009
• 18 Ko R J. Adulterants in Asian patent medicines.  N Engl J Med. 1998;  339(12) 847
• 19 Huang W F, Wen K C, Hsiao M L. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan.  J Clin Pharmacol. 1997;  37(4) 344-350
• 20 Espinoza E O, Mann M-J, Bleasdell B. Arsenic and mercury in traditional Chinese herbal balls.  N Engl J Med. 1995;  333(12) 803-804
• 21 Gertner E, Marshall P S, Filandrinos D, Potek A S, Smith T M. Complications resulting from the use of Chinese herbal medications containing undeclared prescription drugs.  Arthritis Rheum. 1995;  38 614-617
• 22 Kang-Yum E, Oransky S H. Chinese patent medicine as a potential source of mercury poisoning.  Vet Hum Toxicol. 1992;  34(3) 235-238
• 23 Stickel F, Droz S, Patsenker E, Bögli-Stuber K, Aebi B, Leib S L. Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis .  J Hepatol. 2009;  50(1) 111-117
• 24 Wai C T, Tan B H, Chan C L et al.. Drug-induced liver injury at an Asian center: a prospective study.  Liver Int. 2007;  27 465-474
• 25 Chalasani N, Fontana R J, Bonkovsky H L Drug Induced Liver Injury Network (DILIN) et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.  Gastroenterology. 2008;  135(6) 1924-1934, 1934, e1–e4
• 26 Estes J D, Stolpman D, Olyaei A et al.. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure.  Arch Surg. 2003;  138(8) 852-858
• 27 García-Cortés M, Borraz Y, Lucena M I et al.. [Liver injury induced by “natural remedies”: an analysis of cases submitted to the Spanish Liver Toxicity Registry].  Rev Esp Enferm Dig. 2008;  100(11) 688-695
• 28 Melchart D, Linde K, Weidenhammer W, Hager S, Shaw D, Bauer R. Liver enzyme elevations in patients treated with traditional Chinese medicine.  JAMA. 1999;  282(1) 28-29
• 29 Yun Y J, Nah S S, Park J H et al.. Assessment of prescribed herbal medicine on liver function in Korea: a prospective observational study.  J Altern Complement Med. 2008;  14(9) 1131-1136
• 30 Norris W, Paredes A H, Lewis J H. Drug-induced liver injury in 2007.  Curr Opin Gastroenterol. 2008;  24(3) 287-297
• 31 Lucena M I, Garcia-Cortes M, Cueto R, Lopez-Duran J, Andrade R J. Assessment of drug-induced liver injury in clinical practice.  Fundam Clin Pharmacol. 2008;  22 141-158
• 32 Navarro V J, Senior J R. Drug-related hepatotoxicity.  N Engl J Med. 2006;  354(7) 731-739
• 33 Stedman C. Herbal hepatotoxicity.  Semin Liver Dis. 2002;  22(2) 195-206
• 34 Seeff L B. Herbal hepatotoxicity.  Clin Liver Dis. 2007;  11(3) 577-596, vii
• 35 Schiano T D. Hepatotoxicity and complementary and alternative medicines.  Clin Liver Dis. 2003;  7(2) 453-473
• 36 U.S. Food and Drug Administration .Warning on Hydroxycut products. Available at: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm152152.htm Accessed May 31, 2009
• 37 Stevens T, Qadri A, Zein N N. Two patients with acute liver injury associated with use of the herbal weight-loss supplement Hydroxycut.  Ann Intern Med. 2005;  142(6) 477-478
• 38 Dara L, Hewett J, Lim J K. Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements.  World J Gastroenterol. 2008;  14(45) 6999-7004
• 39 Shim M, Saab S. Severe hepatotoxicity due to Hydroxycut: a case report.  Dig Dis Sci. 2009;  54(2) 406-408
• 40 Jones F J, Andrews A H. Acute liver injury associated with the herbal supplement Hydroxycut in a soldier deployed to Iraq.  Am J Gastroenterol. 2007;  102(10) 2357-2358
• 41 Herbalife. Available at: http://herbalife.com Accessed May 31, 2009
• 42 Elinav E, Pinsker G, Safadi R et al.. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity.  J Hepatol. 2007;  47(4) 514-520
• 43 Schoepfer A M, Engel A, Fattinger K et al.. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products.  J Hepatol. 2007;  47(4) 521-526
• 44 Duque J M, Ferreiro J, Salgueiro E, Manso G. [Hepatotoxicity associated with the consumption of herbal slimming products].  Med Clin (Barc). 2007;  128(6) 238-239
• 45 Chao S, Anders M, Turbay M, Olaiz E, McCormack L, Mastai R. Hepatitis aguda asociada al consumo de Herbalife^® a proposito de un caso.  Acta Gastroenterol Latinoam. 2008;  38 274-277
• 46 US Department of Justice, Drug Enforcement Administration (DEA) .Rules 2005-Implementation of the Anabolic Steroid Control Act of 2004. Available at: http://www.deadiversion.usdoj.gov/fed_regs/rules/2005/fr1216.htm Accessed May 31, 2009
• 47 Brown G A, Vukovich M, King D S. Testosterone prohormone supplements.  Med Sci Sports Exerc. 2006;  38(8) 1451-1461
• 48 Shipley A. Steroids detected in dietary tablets. The Washington Post; November 30, 2005 EO1
• 49 Kafrouni M I, Anders R A, Verma S. Hepatotoxicity associated with dietary supplements containing anabolic steroids.  Clin Gastroenterol Hepatol. 2007;  5(7) 809-812
• 50 Ishak K G. Hepatic lesions caused by anabolic and contraceptive steroids.  Semin Liver Dis. 1981;  1(2) 116-128
• 51 Erlinger S. Drug-induced cholestasis.  J Hepatol. 1997;  26(Suppl 1) 1-4
• 52 National Institute on Drug Abuse (NIDA) InfoFacts .Steroids (anabolic-androgenic). Available at: http://www.nida.nih.gov/Infofacts/steroids.html Accessed May 31, 2009
• 53 World Health Organization .WHO Pharmaceuticals Newsletter 2003, No. 03. Available at: http://apps.who.int/medicinedocs/en/d/Js4946e/1.4.html Accessed June 4, 2009
• 54 Gloro R, Hourmand-Ollivier I, Mosquet B et al.. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea.  Eur J Gastroenterol Hepatol. 2005;  17(10) 1135-1137
• 55 Jimenez-Saenz M, Martinez-Sanchez Mdel C. Acute hepatitis associated with the use of green tea infusions.  J Hepatol. 2006;  44(3) 616-617
• 56 Mazzanti G, Menniti-Ippolito F, Moro P A et al.. Hepatotoxicity from green tea: a review of the literature and two unpublished cases.  Eur J Clin Pharmacol. 2009;  65(4) 331-341
• 57 Molinari M, Watt K DS, Kruszyna T et al.. Acute liver failure induced by green tea extracts: case report and review of the literature.  Liver Transpl. 2006;  12(12) 1892-1895
• 58 Sarma D N, Barrett M L, Chavez M L et al.. Safety of green tea extracts: a systematic review by the US Pharmacopeia.  Drug Saf. 2008;  31(6) 469-484
• 59 Javaid A, Bonkovsky H L. Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): a growing concern.  J Hepatol. 2006;  45(2) 334-335, author reply 335–336
• 60 Bonkovsky H L. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis).  Ann Intern Med. 2006;  144(1) 68-71
• 61 Isbrucker R A, Edwards J A, Wolz E, Davidovich A, Bausch J. Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: dermal, acute and short-term toxicity studies.  Food Chem Toxicol. 2006;  44(5) 636-650
• 62 Galati G, Lin A, Sultan A M, O'Brien P J. Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins.  Free Radic Biol Med. 2006;  40 570-580
• 63 Takami S, Imai T, Hasumura M, Cho Y M, Onose J, Hirose M. Evaluation of toxicity of green tea catechins with 90-day dietary administration to F344 rats.  Food Chem Toxicol. 2008;  46(6) 2224-2229
• 64 Swezey R R, Aldridge D E, LeValley S E, Crowell J A, Hara Y, Green C E. Absorption, tissue distribution and elimination of 4-[(3)h]-epigallocatechin gallate in beagle dogs.  Int J Toxicol. 2003;  22(3) 187-193
• 65 Chow H H, Hakim I A, Vining D R et al.. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals.  Clin Cancer Res. 2005;  11(12) 4627-4633
• 66 Cohen S M, O'Connor A M, Hart J, Merel N H, Te H S. Autoimmune hepatitis associated with the use of black cohosh: a case study.  Menopause. 2004;  11(5) 575-577
• 67 Lynch C R, Folkers M E, Hutson W R. Fulminant hepatic failure associated with the use of black cohosh: a case report.  Liver Transpl. 2006;  12(6) 989-992
• 68 Levitsky J, Alli T A, Wisecarver J, Sorrell M F. Fulminant liver failure associated with the use of black cohosh.  Dig Dis Sci. 2005;  50(3) 538-539
• 69 Lontos S, Jones R M, Angus P W, Gow P J. Acute liver failure associated with the use of herbal preparations containing black cohosh.  Med J Aust. 2003;  179(7) 390-391
• 70 Whiting P W, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis.  Med J Aust. 2002;  177 440-443
• 71 Mahady G B, Low Dog T, Barrett M L et al.. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity.  Menopause. 2008;  15(4 Pt 1) 628-638
• 72 Teschke R, Schwarzenboeck A. Suspected hepatotoxicity by Cimicifugae racemosae rhizoma (black cohosh, root): critical analysis and structured causality assessment.  Phytomedicine. 2009;  16(1) 72-84
• 73 Guo L, Shi Q, Fang J L et al.. Review of usnic acid and Usnea barbata toxicity.  J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2008;  26 317-338
• 74 Han D, Matsumaru K, Rettori D, Kaplowitz N. Usnic acid-induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress.  Biochem Pharmacol. 2004;  67(3) 439-451
• 75 Pramyothin P, Janthasoot W, Pongnimitprasert N, Phrukudom S, Ruangrungsi N. Hepatotoxic effect of (+)usnic acid from Usnea siamensis Wainio in rats, isolated rat hepatocytes and isolated rat liver mitochondria.  J Ethnopharmacol. 2004;  90(2-3) 381-387
• 76 Colman E. Dinitrophenol and obesity: an early twentieth-century regulatory dilemma.  Regul Toxicol Pharmacol. 2007;  48(2) 115-117
• 77 Miranda E J, McIntyre I M, Parker D R, Gary R D, Logan B K. Two deaths attributed to the use of 2,4-dinitrophenol.  J Anal Toxicol. 2006;  30(3) 219-222
• 78 Sanchez W, Maple J T, Burgart L J, Kamath P S. Severe hepatotoxicity associated with use of a dietary supplement containing usnic acid.  Mayo Clin Proc. 2006;  81(4) 541-544
• 79 Durazo F A, Lassman C, Han S H et al.. Fulminant liver failure due to usnic acid for weight loss.  Am J Gastroenterol. 2004;  99(5) 950-952
• 80 Favreau J T, Ryu M L, Braunstein G et al.. Severe hepatotoxicity associated with the dietary supplement LipoKinetix.  Ann Intern Med. 2002;  136(8) 590-595
• 81 Neff G W, Reddy K R, Durazo F A, Meyer D, Marrero R, Kaplowitz N. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid.  J Hepatol. 2004;  41(6) 1062-1064
• 82 Bach N, Thung S N, Schaffner F. Comfrey herb tea-induced hepatic veno-occlusive disease.  Am J Med. 1989;  87(1) 97-99
• 83 Weston C FM, Cooper B T, Davies J D, Levine D F. Veno-occlusive disease of the liver secondary to ingestion of comfrey.  Br Med J (Clin Res Ed). 1987;  295(6591) 183
• 84 Zuckerman M, Steenkamp V, Stewart M J. Hepatic veno-occlusive disease as a result of a traditional remedy: confirmation of toxic pyrrolizidine alkaloids as the cause, using an in vitro technique.  J Clin Pathol. 2002;  55(9) 676-679
• 85 Bras G, Jelliffe D B, Stuart K L. Veno-occlusive disease of the liver with nonportal type of cirrhosis, occurring in Jamaica.  Arch Pathol. 1954;  57 285-300
• 86 Tandon B N, Tandon H D, Tandon R K, Narndranathan M, Joshi Y K. An epidemic of veno-occlusive disease of liver in central India.  Lancet. 1976;  2(7980) 271-272
• 87 Mohabbat O, Younos M S, Merzad A A, Srivastava R N, Sediq G G, Aram G N. An outbreak of hepatic veno-occlusive disease in north-western Afghanistan.  Lancet. 1976;  2(7980) 269-271
• 88 Stillman A S, Huxtable R J, Consroe P, Kohnen P, Smith S. Hepatic veno-occlusive disease due to pyrrolizidine (Senecio) poisoning in Arizona.  Gastroenterology. 1977;  73(2) 349-352
• 89 Steenkamp V, Stewart M J, Zuckerman M. Clinical and analytical aspects of pyrrolizidine poisoning caused by South African traditional medicines.  Ther Drug Monit. 2000;  22(3) 302-306
• 90 Ridker P M, Ohkuma S, McDermott W V, Trey C, Huxtable R J. Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements.  Gastroenterology. 1985;  88(4) 1050-1054
• 91 Stickel F, Egerer G, Seitz H K. Hepatotoxicity of botanicals.  Public Health Nutr. 2000;  3(2) 113-124
• 92 Larrey D. Hepatotoxicity of herbal remedies.  J Hepatol. 1997;  26(Suppl 1) 47-51
• 93 U.S. Food and Drug Administration .FDA advises dietary supplement manufacturers to remove comfrey products from the market. Available at: http://www.fda.gov/Food/DietarySupplements/Alerts/ucm111219.htm Accessed May 31, 2009
• 94 Sheikh N M, Philen R M, Love L A. Chaparral-associated hepatotoxicity.  Arch Intern Med. 1997;  157(8) 913-919
• 95 Smith B C, Desmond P V. Acute hepatitis induced by ingestion of the herbal medication chaparral.  Aust N Z J Med. 1993;  23(5) 526
• 96 Batchelor W B, Heathcote J, Wanless I R. Chaparral-induced hepatic injury.  Am J Gastroenterol. 1995;  90(5) 831-833
• 97 Katz M, Saibil F. Herbal hepatitis: subacute hepatic necrosis secondary to chaparral leaf.  J Clin Gastroenterol. 1990;  12(2) 203-206
• 98 Gordon D W, Rosenthal G, Hart J, Sirota R, Baker A L. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications.  JAMA. 1995;  273(6) 489-490
• 99 Kane J A, Kane S P, Jain S. Hepatitis induced by traditional Chinese herbs; possible toxic components.  Gut. 1995;  36(1) 146-147
• 100 Graham-Brown R. Toxicity of Chinese herbal remedies [letter].  Lancet. 1992;  340(8820) 673-674
• 101 Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.  J Clin Epidemiol. 1993;  46(11) 1323-1330
• 102 Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge.  J Clin Epidemiol. 1993;  46(11) 1331-1336
• 103 Maria V AJ, Victorino R MM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis.  Hepatology. 1997;  26(3) 664-669
• 104 Cárdenas A, Restrepo J C, Sierra F, Correa G. Acute hepatitis due to shen-min: a herbal product derived from Polygonum multiflorum.  J Clin Gastroenterol. 2006;  40(7) 629-632
• 105 Rochon J, Protiva P, Seeff L B Drug-Induced Liver Injury Network (DILIN) et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury.  Hepatology. 2008;  48(4) 1175-1183
• 106 Jordan M A, Haywood T. Evaluation of Internet websites marketing herbal weight-loss supplements to consumers.  J Altern Complement Med. 2007;  13(9) 1035-1043
• 107 Gardiner P, Sarma D N, Low Dog T et al.. The state of dietary supplement adverse event reporting in the United States.  Pharmacoepidemiol Drug Saf. 2008;  17(10) 962-970
• 108 Gardiner P, Graham R E, Legedza A T, Eisenberg D M, Phillips R S. Factors associated with dietary supplement use among prescription medication users.  Arch Intern Med. 2006;  166(18) 1968-1974
• 109 Suchard J R, Suchard M A, Steinfeldt J L. Physician knowledge of herbal toxicities and adverse herb-drug interactions.  Eur J Emerg Med. 2004;  11(4) 193-197
• 110 Berman B M, Singh B K, Lao L, Singh B B, Ferentz K S, Hartnoll S M. Physicians' attitudes toward complementary or alternative medicine: a regional survey.  J Am Board Fam Pract. 1995;  8(5) 361-366
• 111 U.S. Food and Drug Administration .MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Available at: http://www.fda.gov/medwatch Accessed May 31, 2009
• 112 U.S. Department of Health and Human Services .Office of Inspector General Report: adverse event reporting for dietary supplements; an inadequate safety valve. Washington, DC; 2001. Available at: http://www.dhhs.gov/oig/oei Accessed June 4, 2009
• 113 Russmann S, Lauterburg B H, Helbling A. Kava hepatotoxicity.  Ann Intern Med. 2001;  135(1) 68-69
• 114 Teschke R, Schwarzenboeck A, Hennermann K H. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases.  Eur J Gastroenterol Hepatol. 2008;  20(12) 1182-1193